Publications by authors named "Vera Rentsch"
Article Synopsis
- CAR T-cell therapy is a standard treatment for patients with refractory or relapsed diffuse large B-cell lymphomas (DLBCL), but outcomes for those who relapse after CAR T are poor and options are limited.
- This study explored the effects of the bispecific CD20xCD3 antibody glofitamab on nine patients who had progressive DLBCL after CAR T-cell therapy, using a maximum of 12 cycles following a single obinutuzumab pre-treatment.
- The results showed that glofitamab is well tolerated with a 67% overall response rate, including complete and partial responses, and it may help boost the activity of residual CAR T-cells in the bloodstream.
